{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:05:30Z","timestamp":1793325930588,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,7,13]],"date-time":"2016-07-13T00:00:00Z","timestamp":1468368000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100006477","name":"National Taiwan University","doi-asserted-by":"publisher","award":["NTU-ICRP-103R7557"],"award-info":[{"award-number":["NTU-ICRP-103R7557"]}],"id":[{"id":"10.13039\/501100006477","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministry of Science and Technology, Taiwan (TW)","award":["MOST 103-2314-B-002-170-MY3"],"award-info":[{"award-number":["MOST 103-2314-B-002-170-MY3"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12885-016-2494-8","type":"journal-article","created":{"date-parts":[[2016,7,13]],"date-time":"2016-07-13T11:55:35Z","timestamp":1468410935000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer"],"prefix":"10.1186","volume":"16","author":[{"given":"Bang-Bin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Shen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Hung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Wu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Fang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Yu","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Wei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shwu-Yuan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Lii","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany Ting-Fang","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,13]]},"reference":[{"key":"2494_CR1","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1126\/science.6823562","volume":"219","author":"DR Senger","year":"1983","unstructured":"Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219:983\u20135.","journal-title":"Science"},{"key":"2494_CR2","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1126\/science.2479986","volume":"246","author":"DW Leung","year":"1989","unstructured":"Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306\u20139.","journal-title":"Science"},{"key":"2494_CR3","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1056\/NEJM197108122850711","volume":"285","author":"J Folkman","year":"1971","unstructured":"Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182\u20136.","journal-title":"N Engl J Med"},{"key":"2494_CR4","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/362841a0","volume":"362","author":"KJ Kim","year":"1993","unstructured":"Kim KJ, Li B, Winer J, Gillett N, Phillips HS, Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362:841\u20134.","journal-title":"Nature"},{"key":"2494_CR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0002-9440(10)63273-7","volume":"165","author":"T Inai","year":"2004","unstructured":"Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol. 2004;165:35\u201352.","journal-title":"Am J Pathol"},{"key":"2494_CR6","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1158\/0008-5472.CAN-11-3406","volume":"72","author":"B Sitohy","year":"2012","unstructured":"Sitohy B, Nagy JA, Dvorak HF. Anti-VEGF\/VEGFR therapy for cancer: reassessing the target. Cancer Res. 2012;72:1909\u201314.","journal-title":"Cancer Res"},{"key":"2494_CR7","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/nm0901-987","volume":"7","author":"RK Jain","year":"2001","unstructured":"Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001;7:987\u20139.","journal-title":"Nat Med"},{"key":"2494_CR8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.1104819","volume":"307","author":"RK Jain","year":"2005","unstructured":"Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58\u201362.","journal-title":"Science"},{"key":"2494_CR9","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1158\/1535-7163.MCT-08-0715","volume":"7","author":"J Ma","year":"2008","unstructured":"Ma J, Waxman DJ. Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther. 2008;7:3670\u201384.","journal-title":"Mol Cancer Ther"},{"key":"2494_CR10","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1093\/annonc\/mdq122","volume":"21","author":"A Chan","year":"2010","unstructured":"Chan A, Miles DW, Pivot X. Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer. Ann Oncol. 2010;21:2305\u201315.","journal-title":"Ann Oncol"},{"key":"2494_CR11","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1634\/theoncologist.2012-0043","volume":"17","author":"S Reddy","year":"2012","unstructured":"Reddy S, Raffin M, Kaklamani V. Targeting angiogenesis in metastatic breast cancer. Oncologist. 2012;17:1014\u201326.","journal-title":"Oncologist"},{"key":"2494_CR12","doi-asserted-by":"publisher","first-page":"3942","DOI":"10.1158\/1078-0432.CCR-07-0278","volume":"13","author":"PV Dickson","year":"2007","unstructured":"Dickson PV, Hamner JB, Sims TL, Fraga CH, Ng CY, Rajasekeran S, et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res. 2007;13:3942\u201350.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2494_CR13","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1158\/1078-0432.CCR-14-2075","volume":"21","author":"YS Lu","year":"2015","unstructured":"Lu YS, Chen TW, Lin CH, Yeh DC, Tseng LM, Wu PF, et al. Bevacizumab preconditioning followed by etoposide and cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy. Clin Cancer Res. 2015;21(8):1851\u20138.","journal-title":"Clin Cancer Res"},{"key":"2494_CR14","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.1200\/JCO.2006.06.8080","volume":"24","author":"N Hylton","year":"2006","unstructured":"Hylton N. Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J Clin Oncol. 2006;24:3293\u20138.","journal-title":"J Clin Oncol"},{"key":"2494_CR15","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/nrclinonc.2012.2","volume":"9","author":"JP O\u2019Connor","year":"2012","unstructured":"O\u2019Connor JP, Jackson A, Parker GJ, Roberts C, Jayson GC. Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies. Nat Rev Clin Oncol. 2012;9:167\u201377.","journal-title":"Nat Rev Clin Oncol"},{"key":"2494_CR16","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1200\/JCO.2001.19.2.551","volume":"19","author":"AG Sorensen","year":"2001","unstructured":"Sorensen AG, Patel S, Harmath C, Bridges S, Synnott J, Sievers A, et al. Comparison of diameter and perimeter methods for tumor volume calculation. J Clin Oncol. 2001;19:551\u20137.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2494_CR17","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00330-011-2249-5","volume":"22","author":"BB Chen","year":"2012","unstructured":"Chen BB, Hsu CY, Yu CW, Wei SY, Kao JH, Lee HS, et al. Dynamic contrast-enhanced magnetic resonance imaging with Gd-EOB-DTPA for the evaluation of liver fibrosis in chronic hepatitis patients. Eur Radiol. 2012;22(1):171\u201380.","journal-title":"Eur Radiol"},{"key":"2494_CR18","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1148\/radiol.13130016","volume":"269","author":"WJ Chung","year":"2013","unstructured":"Chung WJ, Kim HS, Kim N, Choi CG, Kim SJ. Recurrent glioblastoma: optimum area under the curve method derived from dynamic contrast-enhanced T1-weighted perfusion MR imaging. Radiology. 2013;269:561\u20138.","journal-title":"Radiology"},{"key":"2494_CR19","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S","volume":"10","author":"PS Tofts","year":"1999","unstructured":"Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging. 1999;10:223\u201332.","journal-title":"J Magn Reson Imaging"},{"key":"2494_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/biomet\/73.1.13","volume":"73","author":"KYZS Liang","year":"1986","unstructured":"Liang KYZS. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13\u201322.","journal-title":"Biometrika"},{"key":"2494_CR21","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1200\/JCO.2012.46.2762","volume":"31","author":"D Lambrechts","year":"2013","unstructured":"Lambrechts D, Lenz H-J, de Haas S, Carmeliet P, Scherer SJ. Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol. 2013;31:1219\u201330.","journal-title":"J Clin Oncol"},{"key":"2494_CR22","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1093\/neuonc\/nor075","volume":"13","author":"J Narang","year":"2011","unstructured":"Narang J, Jain R, Arbab AS, Mikkelsen T, Scarpace L, Rosenblum ML, et al. Differentiating treatment-induced necrosis from recurrent\/progressive brain tumor using nonmodel-based semiquantitative indices derived from dynamic contrast-enhanced T1-weighted MR perfusion. Neuro Oncol. 2011;13:1037\u201346.","journal-title":"Neuro Oncol"},{"key":"2494_CR23","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1148\/radiol.10100995","volume":"258","author":"BB Chen","year":"2011","unstructured":"Chen BB, Hsu CY, Yu CW, Hou HA, Liu CY, Wei SY, et al. Dynamic contrast-enhanced MR imaging measurement of vertebral bone marrow perfusion may be indicator of outcome of acute myeloid leukemia patients in remission. Radiology. 2011;258:821\u201331.","journal-title":"Radiology"},{"key":"2494_CR24","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/jmri.1880060210","volume":"6","author":"KL Verstraete","year":"1996","unstructured":"Verstraete KL, Van der Woude HJ, Hogendoorn PC, De-Deene Y, Kunnen M, Bloem JL. Dynamic contrast-enhanced MR imaging of musculoskeletal tumors: basic principles and clinical applications. J Magn Reson Imaging. 1996;6:311\u201321.","journal-title":"J Magn Reson Imaging"},{"key":"2494_CR25","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/(SICI)1522-2586(199909)10:3<254::AID-JMRI5>3.0.CO;2-9","volume":"10","author":"JL Evelhoch","year":"1999","unstructured":"Evelhoch JL. Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging. 1999;10:254\u20139.","journal-title":"J Magn Reson Imaging"},{"key":"2494_CR26","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/sj.bjc.6602550","volume":"92","author":"MO Leach","year":"2005","unstructured":"Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A, et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer. 2005;92:1599\u2013610.","journal-title":"Br J Cancer"},{"key":"2494_CR27","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/nbm.2994","volume":"26","author":"R Jain","year":"2013","unstructured":"Jain R. Measurements of tumor vascular leakiness using DCE in brain tumors: clinical applications. NMR Biomed. 2013;26:1042\u20139.","journal-title":"NMR Biomed"},{"key":"2494_CR28","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ccr.2006.11.021","volume":"11","author":"TT Batchelor","year":"2007","unstructured":"Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11:83\u201395.","journal-title":"Cancer Cell"},{"key":"2494_CR29","doi-asserted-by":"publisher","first-page":"5296","DOI":"10.1158\/0008-5472.CAN-09-0814","volume":"69","author":"AG Sorensen","year":"2009","unstructured":"Sorensen AG, Batchelor TT, Zhang WT, Chen PJ, Yeo P, Wang M, et al. A \u201cvascular normalization index\u201d as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res. 2009;69:5296\u2013300.","journal-title":"Cancer Res"},{"key":"2494_CR30","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1093\/jnci\/dji023","volume":"97","author":"JC Miller","year":"2005","unstructured":"Miller JC, Pien HH, Sahani D, Sorensen AG, Thrall JH. Imaging angiogenesis: applications and potential for drug development. J Natl Cancer Inst. 2005;97:172\u201387.","journal-title":"J Natl Cancer Inst"},{"key":"2494_CR31","doi-asserted-by":"crossref","unstructured":"Lin NU, Gelman RS, Younger WJ, Sohl J, Freedman RA, Sorensen AG, et al. Phase II trial of carboplatin (C) and bevacizumab (BEV) in patients (pts) with breast cancer brain metastases (BCBM). J Clin Oncol. 2013;31(suppl; abstr 513). http:\/\/meetinglibrary.asco.org\/content\/83798?media=vm .","DOI":"10.1200\/jco.2013.31.15_suppl.513"},{"key":"2494_CR32","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1186\/s12885-015-1290-1","volume":"15","author":"PF Wu","year":"2015","unstructured":"Wu PF, Lin CH, Kuo CH, Chen WW, Yeh DC, Liao HW, et al. A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis. BMC Cancer. 2015;15:299. doi: 10.1186\/s12885-015-1290-1 .","journal-title":"BMC Cancer"},{"key":"2494_CR33","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1007\/s11095-008-9532-4","volume":"25","author":"J Kamiie","year":"2008","unstructured":"Kamiie J, Ohtsuki S, Iwase R, Ohmine K, Katsukura Y, Yanai K, et al. Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC\/MS\/MS method combined with novel in-silico peptide selection criteria. Pharm Res. 2008;25:1469\u201383.","journal-title":"Pharm Res"},{"key":"2494_CR34","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/j.addr.2004.07.007","volume":"56","author":"H Kusuhara","year":"2004","unstructured":"Kusuhara H, Sugiyama Y. Efflux transport systems for organic anions and cations at the blood-CSF barrier. Adv Drug Deliv Rev. 2004;56:1741\u201363.","journal-title":"Adv Drug Deliv Rev"},{"key":"2494_CR35","first-page":"431","volume":"5","author":"MM Jensen","year":"2015","unstructured":"Jensen MM, Kjaer A. Monitoring of anti-cancer treatment with (18)F-FDG and (18)F-FLT PET: a comprehensive review of pre-clinical studies. Am J Nucl Med Mol Imaging. 2015;5:431\u201356.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"2494_CR36","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.3109\/0284186X.2013.813634","volume":"52","author":"A Kristian","year":"2013","unstructured":"Kristian A, Revheim ME, Qu H, M\u00e6landsmo GM, Engebr\u00e5ten O, Seierstad T, et al. Dynamic (18)F-FDG-PET for monitoring treatment effect following anti-angiogenic therapy in triple-negative breast cancer xenografts. Acta Oncol. 2013;52:1566\u201372.","journal-title":"Acta Oncol"},{"issue":"5","key":"2494_CR37","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1093\/neuonc\/nos012","volume":"14","author":"C Colavolpe","year":"2012","unstructured":"Colavolpe C, Chinot O, Metellus P, Mancini J, Barrie M, Bequet-Boucard C, et al. FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan. Neuro Oncol. 2012;14(5):649\u201357.","journal-title":"Neuro Oncol"},{"key":"2494_CR38","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00259-015-3183-6","volume":"43","author":"OM Henriksen","year":"2016","unstructured":"Henriksen OM, Larsen VA, Muhic A, Hansen AE, Larsson HB, Poulsen HS, et al. Simultaneous evaluation of brain tumour metabolism, structure and blood volume using [(18)F]-fluoroethyltyrosine (FET) PET\/MRI: feasibility, agreement and initial experience. Eur J Nucl Med Mol Imaging. 2016;43:103\u201312.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2494_CR39","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1093\/annonc\/mdt361","volume":"24","author":"B Gerber","year":"2013","unstructured":"Gerber B, Loibl S, Eidtmann H, Rezai M, Fasching PA, Tesch H, et al. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44). Ann Oncol. 2013;24:2978\u201384.","journal-title":"Ann Oncol"},{"key":"2494_CR40","doi-asserted-by":"publisher","first-page":"8136","DOI":"10.1200\/JCO.2005.02.5635","volume":"23","author":"CG Willett","year":"2005","unstructured":"Willett CG, Boucher Y, Duda DG, di Tomaso E, Munn LL, Tong RT, et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol. 2005;23:8136\u20139.","journal-title":"J Clin Oncol"},{"key":"2494_CR41","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.1200\/JCO.2008.21.1771","volume":"27","author":"CG Willett","year":"2009","unstructured":"Willett CG, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Sahani DV, et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol. 2009;27:3020\u20136.","journal-title":"J Clin Oncol"},{"key":"2494_CR42","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/nm988","volume":"10","author":"CG Willett","year":"2004","unstructured":"Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004;10:145\u20137.","journal-title":"Nat Med"},{"key":"2494_CR43","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1038\/nm940","volume":"9","author":"S Gross","year":"2003","unstructured":"Gross S, Gilead A, Scherz A, Neeman M, Salomon Y. Monitoring photodynamic therapy of solid tumors online by BOLD-contrast MRI. Nat Med. 2003;9:1327\u201331.","journal-title":"Nat Med"},{"key":"2494_CR44","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1634\/theoncologist.2010-0029","volume":"15","author":"DG Duda","year":"2010","unstructured":"Duda DG, Willett CG, Ancukiewicz M, di Tomaso E, Shah M, Czito BG, et al. Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. Oncologist. 2010;15:577\u201383.","journal-title":"Oncologist"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2494-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-016-2494-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2494-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2494-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T18:30:42Z","timestamp":1600885842000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-016-2494-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,13]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["2494"],"URL":"https:\/\/doi.org\/10.1186\/s12885-016-2494-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,13]]},"article-number":"466"}}